Clinical Trial Update: A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating peginterferon alfa-2a (Pegasys) in combination with ribavirin for chronic hepatitis C has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-08-04